Search
Now showing items 541-550 of 717
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.
(SPRINGERNATURE, 2023-10-26)
BACKGROUND: Axitinib is an oral vascular endothelial growth factor receptor inhibitor with anti-tumour activity in renal, thyroid, and pancreatic cancer. METHODS: Axi-STS was a pathologically-stratified, non-randomised, ...
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2022-08-15)
PURPOSE: Therapies targeting the androgen receptor (AR) have improved the outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of the constitutively active AR splice variant-7 (AR-V7) has shown ...
Cross-sectional analyses of online appointment booking and repeat prescription ordering user characteristics in general practices of England in the years 2018-2020.
(BMJ, 2023-10-12)
OBJECTIVES: To explore the characteristics of the General Practice Patient Survey (GPPS) respondents using the different functionalities of the online services in the context of England's National Health Service General ...
Consistent and invertible deformation vector fields for a breathing anthropomorphic phantom: a post-processing framework for the XCAT phantom.
(IOP PUBLISHING LTD, 2020-08-13)
Breathing motion is challenging for radiotherapy planning and delivery. This requires advanced four-dimensional (4D) imaging and motion mitigation strategies and associated validation tools with known deformations. Numerical ...
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2022-11-02)
UNLABELLED: Analysis of DNA methylation is a valuable tool to understand disease progression and is increasingly being used to create diagnostic and prognostic clinical biomarkers. While conversion of cytosine to ...
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2023-08-15)
UNLABELLED: Systemic targeted therapy in prostate cancer is primarily focused on ablating androgen signaling. Androgen deprivation therapy and second-generation androgen receptor (AR)-targeted therapy selectively favor the ...
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
(AMER ASSOC CANCER RESEARCH, 2022-12-15)
PURPOSE: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, ...
Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption.
(SPRINGERNATURE, 2023-11-24)
Digital pathology (DP), or the digitization of pathology images, has transformed oncology research and cancer diagnostics. The application of artificial intelligence (AI) and other forms of machine learning (ML) to these ...
A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels.
(SPRINGERNATURE, 2020-08-06)
Pan-cancer genomic analyses based on the magnitude of pathway activity are currently lacking. Focusing on the cell cycle, we examined the DNA mutations and chromosome arm-level aneuploidy within tumours with low, intermediate ...
Immunotherapy of sarcomas with modified T cells.
(LIPPINCOTT WILLIAMS & WILKINS, 2022-07-01)
PURPOSE OF REVIEW: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date. RECENT FINDINGS: Numerous clinical trials are underway evaluating ...